In California, a new bill (SB 17) was introduced seeking to advance the pricing transparency efforts of last year’s SB 1010 and promote fairer market practices for consumers. SB 17 was introduced on the first day of the 2017 Legislative Session. Last session, SB 1010 was delayed moving forward after amendments made it difficult to accomplish the ultimate goal of drug pricing transparency.
California Drug Pricing Transparency Bill Reintroduced for 2017-18 Session
More from CaliforniaMore posts in California »
- OPA Release 2021-2022 Edition Health Care Quality Report Cards for Medical Group Commercial and Medical Group – Medicare
- IHA California Regional Healthcare Cost & Quality Atlas Update Finds Better Quality, Lower Costs When Providers and Health Plans Share Financial Risk
- Study Links Higher Primary Care Spending to Better Care Quality in California
- California to Limit Health Care Costs with Proposed New Office of Health Care Affordability
- California’s Physician Practice Landscape